It is noted that the level of circulating C3 in rats of interventions was decreased to a similar level as that in negative controls, but not lower than that, which indicates that IMRC treatment does not lead to excessive consumption of complement, thus avoiding the side effects of increased infection risk associated with complement exhaustion therapies. The gene discussed is C3; the disease is infection.